Endo seeks efficiency savings, fires 90 staff

26 January 2017

Ireland-incorporated drugmaker Endo International (Nasdaq: ENDP) has continued its drive to realize efficiency savings with a new round of layoffs, focusing on its US-based corporate and R&D functions.

The move follows steps taken last May to restructure the company’s generics and US branded pharmaceutical business units, in which 740 staff were fired, saving the company $60 million in annual costs.

The latest restructuring will reduce the company’s workforce by approximately 90 full-time positions and will result in restructuring cash charges of around $15 to $20 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK